Compare iShares Core High Dividend ETF (HDV) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Inovio Pharmaceuticals Inc — how do they compare? iShares Core High Dividend ETF trades at $28.23, while Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M). The key difference: iShares Core High Dividend ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| HDV | INO | |
|---|---|---|
52-Week High | $28.36 | $2.87 |
52-Week Low | $23.64 | $1.05 |
Market Cap | — | $89.27M |
Sector | — | Health |
Enterprise Value | — | $60.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV trades at $28.18, down 0.25% on the day, with technical indicators showing a bullish trend supported by moving averages. Recent corporate actions include a 1:5 stock split in April 2026 and scheduled dividends for mid-2026. The ETF focuses on high-quality, high-yield U.S. large-cap value stocks, emphasizing defensive sectors like healthcare and energy.
Outlook remains positive due to strong technical momentum and quality screening, but risks include sector concentration in energy, which may introduce volatility. The ETF's low beta and focus on dividend sustainability appeal to income-focused investors, though competition from lower-cost alternatives like SCHD warrants monitoring.
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
